This provides supportive clinical evidence that targeting and inhibiting TXNIP has also anti-diabetic effects in humans with T1D and that (at least in the case of this target) the mouse models used were predictive of the translatability to humans. The gene discussed is TXNIP; the disease is type 1 diabetes mellitus.